The Journal of extra-corporeal technology
-
J Extra Corpor Technol · Mar 2012
Controlled Clinical TrialTimely bolus insulin for glucose control during cardiopulmonary bypass.
Hyperglycemia during cardiopulmonary bypass (CPB) with glucose containing cardioplegia is common; normoglycemia is difficult to maintain and failure to do so may result in worse outcomes. The purpose of this quality improvement initiative was to show that a simple timely insulin bolus is more effective for glucose control during CPB with glucose containing cardioplegia than conventional (not standardized) glucose management in historical case-matched controls. A single bolus of insulin (.2 international units per kilogram; iu/kg) was administered, at the time of aortic cannulation, to 211 consecutive patients undergoing cardiac surgery with CPB and glucose containing cardioplegia. ⋯ Hyperglycemia in the first 6 hours in the intensive care unit was also significantly less frequent in the study group (5; 2.4%) than in the control group (14; 6.6%) (p = .03). Severe hypoglycemia (BG < 2.8 mmol/L; 50.4 mg/dL) occurred in one patient (.47%) in the timely bolus insulin group and five patients (2.3%) in the control group (p = .09). The timely bolus insulin method is more efficacious, but equally safe, in preventing hyperglycemia during CPB with glucose containing cardioplegia, compared with conventional (not standardized) insulin treatment in historical case-matched controls.
-
J Extra Corpor Technol · Mar 2012
Understanding the delicate balance between bleeding and thrombosis: can we use it to our advantage?
Hemostasis remains an issue in cardiac surgery because many patients are preoperatively on platelet-inhibiting drugs, whereas other patients such as those with an evolving acute myocardial infarction present themselves in a more prothrombotic status. Classical laboratory tests such as activated partial thrombin time and plasma thromboplastin are poor in predicting blood loss and bleeding problems postcardiac surgery. This is explained by the fact that these tests are performed on plasma instead of on whole blood. Whole blood coagulation tests are superior in detecting coagulation deficits and bleeding because they take the cellular interaction in the coagulation cascade into account.
-
J Extra Corpor Technol · Dec 2011
Technical description of the use of selective perfusion techniques during the Norwood procedure for hypoplastic left heart syndrome.
Since the introduction of the Norwood procedure for surgical palliation of hypoplastic left heart syndrome in 1983, refinements have been made to the original procedure to improve patient outcomes while still accomplishing the original goals of the procedure. One of these refinements has been the introduction of regional selective perfusion to limit the duration of circulatory arrest times and optimize the regional flow distribution. In this paper we describe our technique for performing selective cerebral and lower body perfusion during the Norwood procedure.
-
J Extra Corpor Technol · Dec 2011
The prognostic value of using the duration of acute kidney injury in cardiac surgery: an example using two antifibrinolytics.
Previously, we reported that the addition of duration to the Acute Kidney Injury Network (AKIN) definition of acute kidney injury (AKI) is a marker for more severe kidney injury and predicts long-term mortality. We aimed to evaluate an example of the utility of adding AKI duration to the AKIN definition by comparing the historical use of aprotinin with Amicar. In a single-center observational study, we followed 4987 consecutive patients undergoing cardiac surgery between 2002 and 2007 for postsurgery AKI. ⋯ Patients receiving aprotinin had evidence of more advanced disease and comorbidity and were more likely to develop AKI and have longer durations of AKI than Amicar (p < .001): 7.0 +/- 11.5 vs. 3.8 +/- 6.0 days (p < .001). Nearest-neighbor propensity matching demonstrated aprotinin had significantly worse 5-year mortality compared with Amicar (relative risk [RR] = 2.09, 95% confidence interval [CI] = 1.65-2.65). AKI duration added to the AKIN definition of AKI may provide the necessary sensitivity and specificity for evaluating renal outcomes in clinical trials.